Development of a radioimmunoassay for human group-II phospholipase A2 and demonstration of postoperative elevation.

Enzyme Pub Date : 1991-01-01 DOI:10.1159/000468890

Y Matsuda, M Ogawa, K Sakamoto, S Yamashita, A Kanda, M Kohno, N Yoshida, J Nishijima, A Murata, T Mori

{"title":"Development of a radioimmunoassay for human group-II phospholipase A2 and demonstration of postoperative elevation.","authors":"Y Matsuda, M Ogawa, K Sakamoto, S Yamashita, A Kanda, M Kohno, N Yoshida, J Nishijima, A Murata, T Mori","doi":"10.1159/000468890","DOIUrl":null,"url":null,"abstract":"<p><p>A radioimmunoassay (RIA) for the determination of human group-II phospholipase A2 (M-PLA2) has been developed. M-PLA2 was purified from human spleen. Monoclonal antibody (IgG) was prepared by fusion of splenic cells from immunized mice with M-PLA2 and the mouse myeloma cell line NS-1. The RIA was carried out by a single antibody method. The assay is sensitive (0.78 micrograms/l), reproducible and specific. In healthy individuals, the serum M-PLA2 concentration ranges from 1.4 to 4.2 micrograms/l, the average being 2.2 +/- 0.1 micrograms/l (mean +/- SE). Using the RIA, we found increased serum M-PLA2 in patients with various infections and malignant tumors. We also showed the postoperative transient elevation of serum M-PLA2 in cases without any infectious complications. The elevation was independent of the surgical procedure or site. The maximum serum M-PLA2 level was seen on the 2nd to 4th postoperative day. In these patients, the serum M-PLA2 and C-reactive protein levels were significantly correlated. The present study indicated that serum M-PLA2 is an acute phase reactant.</p>","PeriodicalId":11933,"journal":{"name":"Enzyme","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000468890","citationCount":"59","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enzyme","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000468890","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 59

Abstract

A radioimmunoassay (RIA) for the determination of human group-II phospholipase A2 (M-PLA2) has been developed. M-PLA2 was purified from human spleen. Monoclonal antibody (IgG) was prepared by fusion of splenic cells from immunized mice with M-PLA2 and the mouse myeloma cell line NS-1. The RIA was carried out by a single antibody method. The assay is sensitive (0.78 micrograms/l), reproducible and specific. In healthy individuals, the serum M-PLA2 concentration ranges from 1.4 to 4.2 micrograms/l, the average being 2.2 +/- 0.1 micrograms/l (mean +/- SE). Using the RIA, we found increased serum M-PLA2 in patients with various infections and malignant tumors. We also showed the postoperative transient elevation of serum M-PLA2 in cases without any infectious complications. The elevation was independent of the surgical procedure or site. The maximum serum M-PLA2 level was seen on the 2nd to 4th postoperative day. In these patients, the serum M-PLA2 and C-reactive protein levels were significantly correlated. The present study indicated that serum M-PLA2 is an acute phase reactant.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

人类ii组磷脂酶A2放射免疫测定的发展和术后升高的证明。

建立了一种测定人ii族磷脂酶A2 (M-PLA2)的放射免疫分析法(RIA)。M-PLA2是从人脾中纯化的。将M-PLA2免疫小鼠脾细胞与小鼠骨髓瘤细胞系NS-1融合制备单克隆抗体(IgG)。RIA采用单抗体法进行。该方法灵敏度高(0.78微克/升)，重现性好，特异性强。健康人血清M-PLA2浓度范围为1.4 ~ 4.2微克/升，平均为2.2 +/- 0.1微克/升(平均+/- SE)。使用RIA，我们发现各种感染和恶性肿瘤患者血清M-PLA2升高。我们还发现，在没有任何感染并发症的病例中，术后血清M-PLA2短暂升高。抬高与手术方式或部位无关。术后第2 ~ 4天血清M-PLA2水平最高。在这些患者中，血清M-PLA2和c反应蛋白水平显著相关。本研究表明血清M-PLA2是急性相反应物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Enzyme

自引率

0.00%

发文量

期刊最新文献

Functional hepatocellular heterogeneity for the production of plasma proteins. Liver cell heterogeneity: functions of non-parenchymal cells. Hepatocyte heterogeneity in the metabolism of carbohydrates. Zonal liver cell heterogeneity. Hepatocyte heterogeneity in the metabolism of amino acids and ammonia.